Previous Article | Next Article 
Molecular and Cellular Biology, May 1999, p. 3842-3847, Vol. 19, No. 5
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Mitochondrial Regulation of Cell Death:
Mitochondria Are Essential for Procaspase 3-p21 Complex Formation
To Resist Fas-Mediated Cell Death
Atsushi
Suzuki,1,2,*
Yumi
Tsutomi,1
Naoe
Yamamoto,3
Tomoko
Shibutani,4 and
Kouichi
Akahane5
Drug Safety Research
Laboratory,1 Project for the Cell Death
Research,2 New Product Research
Laboratory I,3 New Product Research
Laboratory II,4 and New Product Research
Laboratory IV,5 Daiichi Pharmaceutical Co.,
Ltd., Edogawa-ku, Tokyo 134-8630, Japan
Received 28 October 1998/Returned for modification 3 January
1999/Accepted 12 February 1999
 |
ABSTRACT |
Death receptor Fas transduces cell death signaling upon stimulation
by Fas ligand, and this death signaling is mediated by caspase.
Recently, we reported that the cell cycle regulator p21 interacts with
procaspase 3 to resist Fas-mediated cell death. In the present study,
the molecular characterization and functional region of the procaspase
3-p21 complex was further investigated. We observed the p21 expression
in the mitochondrial fraction of HepG2 cells and detected Fas-mediated
cell death only in the presence of actinomycin D. However,
mitochondrial-DNA-lacking HepG2 (MDLH) cells showed this effect even in
the absence of actinomycin D. Both p21 and procaspase 3 were expressed
in MDLH cells, but the procaspase 3-p21 complex formation was not
observed. Interestingly, the resistance to Fas-mediated cell death in
the MDLH cells without actinomycin D was recovered after microinjection
of HepG2-derived mitochondria into the MDLH cells. We conclude that
mitochondria are necessary for procaspase 3-p21 complex formation and
propose that the mitochondrial role during cell death is not only death induction but also death suppression.
 |
INTRODUCTION |
Cell death is an essential
phenomenon for cell homeostasis, as well as cell growth, and its
occurrence during embryonic and postembryonic development has been well
documented (20, 39). There are two distinct processes
leading to cell death: apoptotic cell death and necrotic cell death
(39). Apoptotic cell death is accompanied by the
condensation and/or fragmentation of nuclei, as well as apoptotic body
formation and chromosomal DNA fragmentation into 180-bp oligomers
(39). Multiple studies have demonstrated the important role
of apoptotic cell death in various disease states and physiological
cell death (21), and many factors involved with the death
signaling have been identified.
Fas, a transmembrane protein belonging to the tumor necrosis
factor/nerve growth factor receptor family (21), transduces the death signaling upon stimulation by Fas ligand or an agonistic Fas
antibody, such as the CH-11 clone (41). The molecular
mechanism of Fas-mediated apoptosis has been extensively investigated.
Caspase is the term used for the interleukin-1
converting enzyme
(ICE)/CED-3 cysteine proteinase family (1). During death
induction, the sequential activation of the ICE and CPP32 subfamilies
has been reported (6, 27, 29, 31, 33), and this phenomenon
is known as the "ICE cascade." At present, 10 genes have been
identified as part of the caspase family, and the CPP32 subfamily,
including caspase 3 (CPP32/Yama/Apopain [7, 23]) and
caspase 8 (FLICE/MACH [2, 19]), in particular acts as
the dominant regulator in the death signaling. Therefore, the
regulation of CPP32 subfamily activation is an especially important
focus for cell death research.
Among the members of the CPP32 subfamily, caspase 3 is especially
important in the understanding of apoptotic cell death because of its
variant substrate specificity. Cytoplasmic serine proteinase (32), caspase 8 (38), and/or
cytotoxic-T-lymphocyte-derived granzyme B (4) proteolyses
caspase 3 for its activation, and activated caspase 3 proteolyses
and/or activates poly(ADP-ribose) polymerase (37), lamin
(14), and/or DFF (16) to induce apoptotic cell death.
Recently, we reported that the cell cycle regulator p21
(Sdi1/CIP1/WAF1) and the IAP gene family ILP act as inactivators of caspase 3 (35, 36). p21 is especially unique in that it
interacts with only procaspase 3 by each N-terminal sequence and
suppresses its activation by the masking of the cytoplasmic serine
proteinase-cleaving site (35, 36). Thus, the activation of
caspase 3 is regulated by p21, and procaspase 3-p21 complex formation
is an essential system for the cell death since cell survival is a
result of cell death suppression (35). In the present study,
we further characterized the death suppression machinery by procaspase
3-p21 complex formation. Our results suggest that mitochondria play key
role in procaspase 3-p21 complex formation.
 |
MATERIALS AND METHODS |
Cell line and culture.
Human hepatoma HepG2 cells were
supplied by Yoshihide Tsujimoto (10) and were maintained in
RPMI 1640 medium (GIBCO-BRL) supplemented with 10% heat-inactivated
fetal calf serum (FCS; GIBCO-BRL) in a humidified atmosphere of 5%
CO2 and 95% air.
Preparation of HepG2 cells lacking mitochondrial DNA.
Preparation of the HepG2 cells lacking mitochondrial DNA (MDLH) was
done as previously described (5, 11, 13). HepG2 cells were
cultured in RPMI 1640 medium containing ethidium bromide (0.4 µg/ml)
for about 2 months. The loss of mitochondrial DNA was determined by use
of Southern blotting analysis, cell cycle arrest in conditioned medium,
and cell growth recovery in uridine-containing medium.
Immunofluorescence analysis of p21.
Cellular localization of
p21 was investigated by immunofluorescence. HepG2 cells were fixed with
cold fix solution (95% ethyl hydroxide, 5% acetyl hydroxide) for 30 min and then blocked with mouse serum for 2 h. Anti-human p21
antibody (Santa Cruz Biotechnology) was diluted 1/20 with
phosphate-buffered saline (PBS) and incubated with the fixed HepG2
cells for 18 h. Cellular localization of p21 was detected by
fluorescein isothiocyanate (FITC)-labeled anti-mouse immunoglobulin G
IgG by confocal fluorescence microscopy (Leica Japan, Tokyo, Japan). In
the present study, nuclei and mitochondria were also detected with
propidium iodide (PI) and MitoTracker RED (Molecular Probe, Inc.).
Preparation of fractionated proteins.
Cells were collected,
washed with ice-cold PBS, and then suspended in buffer I (2 mM EDTA, 10 mM Tris-HCl; pH 7.5). After incubation on ice for 10 min, an equal
volume of buffer II (0.5 M sucrose, 0.1 M KCl, 10 mM MgCl2,
2 mM CaCl2, 2 mM EDTA, 10 mM Tris-HCl; pH 7.5) was added.
The nuclear-rich fraction was pelleted by centrifugation (2,700 rpm for
10 min). The supernatant was removed and placed in a separate tube and
again centrifuged (43,000 rpm for 90 min). The supernatant was
collected as the cytosol-rich fraction, and the pellet was dissolved in
buffer III (8 mM CHAPS {3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate} 150 mM NaCl, 0.1 M sucrose, 2 mM EDTA, 10 mM Tris-HCl; pH 7.5) and incubated at 4°C for 2 h. The membrane-rich fraction was then collected by centrifugation (43,000 rpm for 60 min). Mitochondria were
collected as previously described (8), and the proteins were
extracted with 1% Nonidet P40-containing PBS. Each fractionation was
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 5 to 20% gels, and p21-expression was detected by immunoblotting analysis with anti-human p21 antibody and the ECL detection system (Amersham).
Immunoblotting analysis.
Sample proteins separated by
SDS-PAGE were transferred onto nitrocellulose membranes with a semidry
blotting system. The membranes were blocked with PBS containing 5%
(wt/vol) skim milk at room temperature for 1 h, washed with a
mixture of PBS and 0.05% Tween 20 (Tween-PBS; Sigma), and then
incubated overnight at room temperature with each antibody diluted with
PBS. After being washed with Tween-PBS, the membranes were incubated
with 1,000-fold-diluted biotinylated anti-mouse IgG antibody
(BioSource), washed with Tween-PBS, and then incubated with
avidin-horseradish peroxidase (Vector Laboratories) at room temperature
for 1 h. The membranes were washed with Tween-PBS and then
developed with the ECL system.
Immunoprecipitation analysis.
Anti-caspase 3 antibody
(Transduction Laboratory) or anti-p21 antibody (Santa Cruz) was mixed
with 1 mg of protein from each cell extract for 30 min. Protein
A-Sepharose was then added, and the mixture was incubated for 2 h.
The immunoprecipitates were heated in SDS sample buffer and separated
on 5 to 20% polyacrylamide gels. After transfer, the membranes were
immunoblotted, washed with Tween-PBS, and developed by using the ECL
system (Amersham).
 |
RESULTS |
Cellular localization of p21.
Immunofluorescence analysis was
performed to localize the p21 in HepG2 cells. When cells were stained
with anti-human p21 antibody, p21 expression was detected in the nuclei
and cytoplasm (Fig. 1). In the present
study, HepG2 cells were stained with PI (nuclear marker) or MitoTracker
Red (dominant marker for mitochondria). To further localize the p21,
immunoblotting analysis of cellular fractionations was performed. As
shown in Fig. 2, p21 expression was
detected in nuclear, cytoplasmic, and mitochondrial proteins but not in
the membrane proteins.

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 1.
Immunofluorescence analysis of p21. HepG2 cells were
stained with FITC-labeled anti-human p21 antibody (green staining in
panels A and B). Cells were also stained with MitoTracker Red (a
dominant marker for mitochondria [red in panel A]) and PI (nuclear
marker [red in panel B]). After the staining, cells were examined by
confocal fluorescence microscopy.
|
|

View larger version (75K):
[in this window]
[in a new window]
|
FIG. 2.
Immunoblotting analysis of p21. Nuclear (Nuc.),
cytoplasmic (Cyt.), membrane (Mem.), and mitochondrial (Mit.) proteins
were collected from HepG2 cells and then separated by SDS-PAGE. After
the SDS-PAGE separation, the expression of p21 (top panel), lamin
(middle panel, nuclear protein marker), and actin (bottom panel,
cytoplasmic protein marker) were examined by immunoblotting.
|
|
Fas-mediated cell death in MDLH cells.
The mitochondrial
localization of p21 in HepG2 cells was of particular interest, and the
role of mitochondrial p21 was further examined. We prepared
mitochondrial-DNA-lacking HepG2 (MDLH) cells by a previously described
method (5, 11, 13). As shown in Fig.
3A, ethidium bromide treatment (for about
2 months) downregulated cell growth in the HepG2-conditioned medium
(RPMI 1640, 10% FCS), and cell growth was restored by the addition of
uridine. These results are consistent with previous observations
(5, 11, 13). In addition, Southern blotting analysis
revealed that cellular DNA extracted from the MDLH cells did not
contain mitochondrial DNA (data not shown). Thus, we established MDLH
cells as mitochondrial-DNA-lacking HepG2 cells.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of mitochondrial DNA in Fas-mediated cell death.
(A) Preparation of MDLH cells. HepG2 cells were treated with 0.4 µg
of ethidium bromide for about 2 months. After this treatment, cell
growth in the conditioned medium (RPMI 1640, 10% FCS) with ( ) or
without ( ) 50 µg of uridine per ml was measured by using trypan
blue. (B) Fas-mediated cell death in HepG2 and MDLH cells. HepG2
(circles) and MDLH (squares) cells were treated with various
concentrations of agonistic Fas antibody (CH-11 clone) in the presence
(solid symbols) or absence (open symbols) of 0.5 µg of actinomycin D
per ml for 24 h. After treatment, cell viability was measured with
Hoechst 33342-PI staining. (C) Fas-mediated cell death in HepG2 and
MDLH cells, and HepG2 cytoplast. HepG2 and MDLH cells and HepG2
cytoplasts were treated with 1 µg of CH-11 clone per ml in the
presence (solid column) or absence (open column) of 0.5 µg of
actinomycin D per ml for 24 h. After treatment, cell death
induction was measured by using Merocyanine 540.
|
|
Fas-mediated cell death in the HepG2 and MDLH cells, as well as in
HepG2 cytoplasts, was investigated (Fig.
3B and C). HepG2
cells showed
Fas-mediated cell death only in the presence of the
de novo protein
synthesis inhibitor (transcriptional inhibitor)
actinomycin D, a
finding consistent with previous reports (
10,
35).
Interestingly, however, MDLH cells showed the Fas-mediated
cell death
both in the presence and in the absence of actinomycin
D. In contrast,
cells lacking nuclear DNA (HepG2 cytoplasts prepared
by a previously
described method [
12]) showed the same trend
as the
HepG2 cells. These results suggest an involvement of mitochondrial
DNA
in the resistance to Fas-mediated cell death of the HepG2
cell.
Involvement of p21 on mitochondria in the resistance to
Fas-mediated cell death.
Our results strongly suggested an
involvement of the mitochondria in the resistance to the Fas-mediated
cell death of HepG2 cells. To further examine the physiological role of
mitochondria during Fas-mediated cell death, HepG2-derived mitochondria
were microinjected into MDLH cells. Under these conditions,
Fas-mediated cell death was encountered only in the presence of
actinomycin D (Fig. 4A). We also
demonstrated that microinjection of p21 rescued HepG2 cells from
Fas-mediated cell death even in the presence of actinomycin D. However,
its injection into MDLH cells did not rescue them from Fas-mediated
cell death (Fig. 4B). Further, mitochondria microinjected into MDLH
cells suppressed Fas-mediated cell death, but mitochondria treated with
p21 monoclonal antibody did not (Fig. 4C). These results suggest that
mitochondria are essential for the p21-induced death suppression.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 4.
Effect of HepG2-derived mitochondrion microinjection
into MDLH cells. (A) MDLH cells were microinjected with (+Mit) or
without ( Mit) HepG2-derived mitochondria. (B) p21 was microinjected
into HepG2 or MDLH cells. (C) HepG2-derived mitochondria were treated
with p21 antibody (p21 Ab) or without it (alone) for 4 h on ice
and then were microinjected into MDLH cells. After each microinjection,
cells were treated with 1 µg of CH-11 clone per ml in the presence
(solid columns) or absence (open columns) of 0.5 µg of actinomycin D
per ml for 24 h, and then cell viability was measured by the
Hoechst 33342-PI staining procedure.
|
|
Mitochondria are essential for procaspase 3-p21 complex
formation.
These results demonstrate that mitochondria are
involved in the resistance to Fas-mediated cell death in HepG2 cells.
We had previously reported that procaspase 3-p21 complex formation
contributes to the resistance to Fas-mediated cell death
(35), and p21 expression was encountered in the
mitochondrial fraction of HepG2 cells in the current study (Fig. 1 and
2). Therefore, we investigated the effect of mitochondria in procaspase
3-p21 complex formation. Both HepG2 and MDLH cells showed expression of
p21 and procaspase 3, but procaspase 3-p21 complex formation was
encountered only in the HepG2 cells and not in the MDLH cells (Fig. 5A
to D). However, MDLH cells showed
procaspase 3-p21 complex formation when cells were microinjected with
HepG2-derived mitochondria (Fig. 5E). These results strongly suggest
that mitochondria are essential for procaspase 3-p21 complex formation
to resist Fas-mediated cell death.

View larger version (70K):
[in this window]
[in a new window]
|
FIG. 5.
Procaspase 3-p21 complex formation in HepG2 and MDLH
cells. Coimmunoprecipitation (A and B) and immunoblotting (C and D)
analysis were performed to investigate the effect of mitochondrial DNA
in procaspase 3-p21 complex formation. p21 (A) or caspase 3 (B)
immunoprecipitates collected from HepG2 or MDLH cells were separated by
SDS-PAGE. Immunoblotting with antibodies to caspase 3 (A) or p21 (B)
was then performed. Each cell extract was also separated by SDS-PAGE
and then immunoblotted with antibodies to caspase 3 (C) or p21 (D). (E)
MDLH cells were microinjected with (+) or without ( ) HepG2-derived
mitochondria, and then p21 (left) or caspase 3 (right)
immunoprecipitates were separated by SDS-PAGE. After SDS-PAGE, an
immunoblotting procedure was performed with antibody to caspase 3 (left) or p21 (right) to examine procaspase-p21 complex formation. Bars
on the left side show the positions of the protein markers: 45, 30, and
20.1 kDa from top to bottom.
|
|
 |
DISCUSSION |
Death receptor Fas transduces cell death signaling into cells upon
stimulation by Fas ligand and is involved with various physiological
cell death and disease states (21, 30, 34). Recent studies
revealed various death-associated factors. Caspase, a member of the
ICE/CED-3 cysteine proteinase family (1), is an essential
factor in Fas-mediated cell death signaling (20). There are
three subfamilies known as the ICE, CPP32, and ICH-1 subfamilies. Among
the members of the CPP32 subfamily of caspase, caspase 3 (CPP32/Yama/Apopain) is important in cell death induction. Caspase 3 proteolyses and/or activates poly(ADP-ribose) polymerase (37), lamin (14), and/or DFF (16), and
its activation is triggered by cytoplasmic serine proteinase
(32), cytotoxic-T-lymphocyte-derived granzyme B
(4), and/or caspase 8 (FLICE/MACH [38]).
Recently, we reported that activation of caspase 3 during Fas-mediated
cell death was regulated by the cell cycle regulator p21 and the IAP gene family ILP (35). The N-terminal region (16- to
33-amino-acid sequence) binds to the p3 region of procaspase 3, and ILP
binds to the caspase 3-p17 region, including the active site
(36). The inactivation mechanism of p21 is especially unique
that p21 directly interacts with only procaspase 3 and not with
activated caspase 3 (35). In addition, p21 protects
procaspase 3 from caspase 3-activating cytoplasmic serine proteinase
(32, 36). Therefore, we further investigated the
inactivation of caspase 3 by p21 in the present study.
We examined the HepG2 cellular localization of p21 by using
immunofluorescence and immunoblotting methods and observed p21 expression in nuclear, cytoplasmic, and mitochondrial fraction. p21 was
identified originally as a cyclin-dependent-kinase (Cdk) inhibitor. It
interacts with Cdk and proliferating cell nuclear antigen (PCNA) to
induce cell cycle arrest (3, 17, 22). Therefore, the nuclear
p21 is most likely complexed with Cdk and PCNA, whereas the cytoplasmic
p21 remains unbound. As described above, we demonstrated p21 expression
in the mitochondrial fraction of HepG2 cells. This is notable since
characterization of mitochondrial p21 has not been reported and recent
cell death investigations indicate that mitochondria play an important
role in cell death signaling (9).
To investigate the effect of mitochondrial p21 in Fas-mediated cell
death, we prepared MDLH cells. HepG2 cells show Fas-mediated cell death
upon stimulation by the agonistic anti-human Fas antibody CH-11 clone
(41) only in the presence of the de novo protein synthesis
inhibitor (transcriptional inhibitor) actinomycin D (10,
35). This resistance to Fas-mediated cell death in the absence of
actinomycin D is due to caspase 3 inactivation by p21 and ILP
(35). In the present study, however, Fas-mediated cell death
in the absence of actinomycin D was encountered in the MDLH cells. In
contrast, nuclear-DNA-lacking HepG2 cells (HepG2 cytoplasts) also
showed Fas-mediated cell death only in the presence of actinomycin D. On the basis of these results, we suggest that mitochondria are
necessary for the resistance to Fas-mediated cell death of HepG2 cells
and that the mitochondrial regulation of cell death involves not only
death induction but also death suppression. The role of mitochondria
during cell death is death induction by caspase 3 activation. This
activation is induced by mitochondrial factors, such as cytochrome
c and AIF (9, 15, 42), and Bcl-2 suppresses this
step (26, 28, 40). However, a mitochondrial factor(s) is not
required for caspase 3 activation in all cases of cell death, since
caspase 8 (FLICE/MACH) and cytotoxic-T-lymphocyte-derived granzyme B
can directly activate caspase 3 without the influence of mitochondria
(4, 38). Therefore, we also suggest that Fas-mediated cell
death induction in HepG2 cells does not require the presence of
mitochondria and that caspase 3 activation in HepG2 cells is triggered
by a cytoplasmic serine proteinase (32) and caspase 8.
We also performed microinjection of mitochondria to further investigate
their role in resistance to Fas-mediated cell death. As described
above, MDLH cells showed the Fas-mediated cell death both in the
presence and in the absence of actinomycin D. In contrast, intact HepG2
cells showed this only in the presence of actinomycin D. When intact
HepG2-derived mitochondria were microinjected into MDLH cells,
Fas-mediated cell death in MDLH cells was induced only in the presence
of actinomycin D. Thus, MDLH cells reacquired the resistance due to
exogenous intact mitochondria. These results strongly suggest that the
resistance to Fas-mediated cell death encountered in HepG2 cells is
regulated by mitochondria. In addition, p21 suppressed Fas-mediated
cell death in HepG2 cells but not in MDLH cells, suggesting that
p21-induced death suppression requires mitochondria. Actually, p21
which interacted with mitochondria suppressed Fas-mediated cell death,
since exogenous mitochondria did not rescue MDLH cells from
Fas-mediated cell death when p21 on exogenous mitochondria was masked
with its antibody. These results strongly suggest that p21, especially
expressed on mitochondria, is important for the suppression of
Fas-mediated cell death as a result of caspase 3 inactivation.
In our previous study (35) and in the present study, we
demonstrated that an important factor for the caspase 3 inactivation, p21, was detected in the mitochondrial fraction. Cells lacking mitochondrial DNA did not show the resistance to Fas-mediated cell
death, but resistance occurred after the microinjection of intact
HepG2-derived mitochondria. These results led us to the possibility
that mitochondria play an essential role in procaspase 3-p21 complex
formation. As shown in Fig. 5, we demonstrated that MDLH cells could
not form the procaspase 3-p21 complex. Since expression of both p21 and
procaspase 3 was detected in MDLH cells, the interruption of procaspase
3-p21 complex formation in MDLH cells is most likely not due to the
absence of either protein, whereas MDLH cells showed procaspase 3-p21
complex formation only when HepG2-derived mitochondria were
microinjected into MDLH cells. We therefore suggest that the procaspase
3-p21 complex formation to resist Fas-mediated cell death is induced
directly by mitochondria.
The mitochondrion is an organelle essential for cell growth and energy
supply (5). Recently, mitochondria were additionally reported to be a cell-death-inducing organelle. During cell death signaling, mitochondrial damage, such as the decreased mitochondrial membrane potential, occurs at an early step (24, 28), and the release of death inducers such as cytochrome c and AIF
(26, 40) can activate caspase. This early mitochondrial
damage during cell death initiation is intriguing, partly because
mitochondrial parasitism during evolution was first suggested some time
ago (18). Is the role of mitochondria death induction and/or
energy supply? Some viruses operate the death suppression system when they infect host cells, such as the death suppressor expression induced
by the cowpox crmA virus (25). Do mitochondria
also alter the death suppression system? Our conclusions regarding these possibilities are addressed schematically in Fig.
6. p21 is an essential factor for caspase
3 inactivation and interacts with mitochondria via an unknown
mitochondrial protein which acts as the adapter. Cells lacking
mitochondrial DNA showed Fas-mediated cell death even in the absence of
actinomycin D, and procaspase 3-p21 complex formation does not occur.
p21 does not contain a membrane-associated region in its sequence, so a
physical interaction between mitochondria and p21 may be mediated by a
mitochondrial protein since procaspase 3-p21 complex formation did not
occur in the absence of mitochondrial DNA. We suggest that the death suppression (caspase 3 inactivation) machinery, i.e., the procaspase 3-p21 complex formation, occurs at the mitochondria and that the mitochondrial regulation of cell death is not only death induction but
also death suppression. In addition, we propose that mitochondria are
involved with cell survival due to the support of the procaspase 3-p21
complex formation to resist Fas-mediated cell death.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 6.
Schematic model of cell death and cell survival
regulated by mitochondria. Fas-mediated cell death signaling is
suppressed by procaspase 3-p21 complex formation on mitochondria. p21
interacts with mitochondria via a mitochondrial adapter protein (MAP).
Due to procaspase 3-p21 complex formation, the cell is protected from
death stimulation and can survive (cell survival). After estrangement
of the procaspase 3-p21 complex formation (as with actinomycin D
treatment), Fas-mediated cell death signaling is transduced and the
cell dies (cell death).
|
|
In the present study, we demonstrated that procaspase 3-p21 complex
formation occurred in mitochondria via a mitochondrial adapter protein
and that the estrangement of this complex is necessary for the
transduction of cell death signaling. We found that the estrangement of
procaspase 3-p21 complex formation was induced by the downregulation of
p21 as a result of actinomycin D treatment (35). This
evidence is important for the understanding of the molecular machinery
of both cell death and cell survival. Therefore, it will be useful to
identify the mitochondrial adapter protein and to study further the
estrangement signal of the procaspase 3-p21 complex.
 |
ACKNOWLEDGMENTS |
We thank Yoshihide Tsujimoto, Osaka University Medical School,
for human hepatoma HepG2 cells; Shigeomi Shimizu, Osaka University Medical School, for his valuable advice about the preparation of MDLH
cells; Naomi Haga, University of Tokyo, for his comments about
experiments with mitochondria; Hiroko Katoh, Leica Co., Ltd., for her
technical support of confocal-fluorescence microscopy; and Masayuki
Miura, Osaka University of Medical School, and Mitsuru Furusawa,
Daiichi Pharmaceutical Co., Ltd., for their valuable discussions.
The preparation of the manuscript was supported by the Idest Inc.,
Edmond, Okla.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Drug Safety
Research Laboratory, Daiichi Pharmaceutical Co., Ltd., Tokyo R&D
Center, Kitakasai 1-16-13, Edogawa-ku, Tokyo 134-8630, Japan. Phone:
81-3-5696-9167. Fax: 81-3-5696-8335. E-mail:
LEB00373{at}nifty.ne.jp.
 |
REFERENCES |
| 1.
|
Alnemri, E. S.,
D. J. Livingston,
D. W. Nicholson,
G. Salvesen,
N. A. Thornbery,
W. W. Wong, and J. Yuan.
1996.
Human ICE/CED-3 protease nomenclature.
Cell
87:171[Medline].
|
| 2.
|
Boldin, M. P.,
T. M. Goncharov,
Y. V. Golstev, and D. Wallach.
1996.
Involvement of MACH, a novel MORT-1/FADD-interacting protease, in Fas/APO-1 and TNF receptor-induced cell death.
Cell
85:803-815[Medline].
|
| 3.
|
Chen, J.,
P. K. Jackson,
M. W. Kirschner, and A. Dutta.
1995.
Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA.
Nature
374:386-388[Medline].
|
| 4.
|
Darmon, A. J.,
D. W. Nicholson, and R. C. Bleackley.
1995.
Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B.
Nature
377:446-448[Medline].
|
| 5.
|
Desjardins, P.,
E. Frost, and R. Morais.
1985.
Ethidium bromide-induced loss of mitochondrial DNA from primary chicken embryo fibroblasts.
Mol. Cell. Biol.
5:1163-1169[Abstract/Free Full Text].
|
| 6.
|
Enari, M.,
R. V. Talanian,
W. W. Wong, and S. Nagata.
1996.
Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis.
Nature
380:723-726[Medline].
|
| 7.
|
Fernandes-Alnemri, T.,
G. Litwack, and E. S. Alnemri.
1994.
CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 -converting enzyme.
J. Biol. Chem.
267:30761-30764[Abstract/Free Full Text].
|
| 8.
|
Fleisher, S., and M. Kervina.
1974.
Subcellular fractionation of rat liver.
Methods Enzymol.
31:6-41[Medline].
|
| 9.
|
Green, D. R., and J. C. Reed.
1998.
Mitochondria and apoptosis.
Science
281:1309-1312[Abstract/Free Full Text].
|
| 10.
|
Hasegawa, J.,
S. Kamada,
W. Kamiike,
S. Shimizu,
T. Imazu,
H. Matsuda, and Y. Tsujimoto.
1996.
Involvement of CPP32/Yama(-like) proteases in Fas-mediated apoptosis.
Cancer Res.
56:1713-1718[Abstract/Free Full Text].
|
| 11.
|
Jacobson, M. D.,
J. F. Burne,
M. P. King,
T. Miyashita,
J. C. Reed, and M. C. Raff.
1993.
Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA.
Nature
361:365-369[Medline].
|
| 12.
|
Jacobson, M. D.,
J. F. Burne, and M. C. Raff.
1994.
Programmed cell death and Bcl-2 protection in the absence of a nucleus.
EMBO J.
13:1899-1910[Medline].
|
| 13.
|
King, M. P., and G. Attardi.
1989.
Human cells lacking mtDNA: Repopulation with exogenous mitochondria by complementation.
Science
246:500-503[Abstract/Free Full Text].
|
| 14.
|
Lazebnik, Y. A.,
A. Takahashi,
R. D. Moir,
R. D. Goldman,
G. G. Poirier,
S. H. Kaufmann, and W. C. Earnshaw.
1995.
Studies of lamin proteinase reveal multiple parallel biochemical pathways during apoptosis.
J. Biol. Chem.
92:9042-9046.
|
| 15.
|
Liu, X.,
C. N. Kim,
J. Yang,
R. Jemmerson, and X. Wang.
1996.
Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c.
Cell
86:147-157[Medline].
|
| 16.
|
Liu, X.,
H. Zou,
C. Slaughter, and X. Wang.
1997.
DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis.
Cell
89:175-184[Medline].
|
| 17.
|
Luo, Y.,
J. Hurwitz, and J. Massague.
1995.
Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1.
Nature
375:159-161[Medline].
|
| 18.
|
Margulis, L.
1975.
Symbiotic theory of the origin of eukaryotic organelles; criteria for proof.
Symp. Soc. Exp. Biol.
29:21-38.
|
| 19.
|
Muzio, M.,
A. M. Chinnaiyan,
F. C. Kischkel,
K. O'Rourke,
A. Shevchenko,
J. Ni,
C. Scaffidi,
J. D. Bretz,
M. Zhang,
R. Gentz,
M. Mann,
P. H. Krammer,
M. E. Peter, and V. M. Dixit.
1996.
FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex.
Cell
85:817-827[Medline].
|
| 20.
|
Nagata, S.
1997.
Apoptosis by death factor.
Cell
88:355-365[Medline].
|
| 21.
|
Nagata, S., and P. Golstein.
1995.
The Fas death factor.
Science
267:1449-1456[Abstract/Free Full Text].
|
| 22.
|
Nakanishi, M.,
R. S. Robetorye,
G. R. Adami,
O. M. Pereira-Smith, and J. R. Smith.
1995.
Identification of the active region of the DNA synthesis inhibitory gene p21Sdi1/CIP1/WAF1.
EMBO J.
14:555-563[Medline].
|
| 23.
|
Nicholson, D. W.,
A. Ali,
N. A. Thornbery,
J. P. Vaillancourt,
C. K. Ding,
M. Gallant,
Y. Gareau,
P. R. Griffin,
M. Labelle,
Y. A. Lazebnic,
N. A. Munday,
S. M. Raju,
M. E. Smulson,
T. T. Yamin,
V. L. Yu, and D. K. Miller.
1995.
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis.
Nature
376:37-43[Medline].
|
| 24.
|
Petit, P. X.,
H. Lecoeur,
E. Zorn,
C. Dauguet,
B. Mignotte, and M.-L. Gougeon.
1995.
Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis.
J. Cell Biol.
130:157-167[Abstract/Free Full Text].
|
| 25.
|
Ray, C. A.,
R. A. Black,
S. R. Kronheim,
T. A. Greenstreet,
P. R. Sleath,
G. S. Salvesen, and D. J. Pickup.
1992.
Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 converting enzyme.
Cell
69:597-604[Medline].
|
| 26.
|
Shimizu, S.,
Y. Eguchi,
W. Kamiike,
Y. Funahashi,
A. Mignon,
V. Lacronique,
H. Matsuda, and Y. Tsujimoto.
1998.
Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton flux.
Proc. Natl. Acad. Sci. USA
95:1455-1459[Abstract/Free Full Text].
|
| 27.
|
Shimizu, S.,
Y. Eguchi,
W. Kamiike,
H. Matsuda, and Y. Tsujimoto.
1996.
Bcl-2 expression prevents activation of ICE protease cascade.
Oncogene
12:2251-2257[Medline].
|
| 28.
|
Shimizu, S.,
Y. Eguchi,
W. Kamiike,
S. Waguri,
Y. Uchiyama,
H. Matsuda, and Y. Tsujimoto.
1996.
Bcl-2 blocks loss of mitochondrial membrane potencial while ICE inhibitors act at a different step during inhibition of death induced by respiratory chain inhibitors.
Oncogene
13:21-29[Medline].
|
| 29.
|
Suzuki, A.
1997.
Amyloid -protein induces necrotic cell death mediated by ICE cascade in PC12 cells.
Exp. Cell Res.
234:507-511[Medline].
|
| 30.
|
Suzuki, A.,
M. Enari,
Y. Eguchi,
A. Matsuzawa,
S. Nagata,
Y. Tsujimoto, and T. Iguchi.
1996.
Involvement of Fas in regression of vaginal epithelia after ovariectomy and during an estrous cycle.
EMBO J.
15:211-215[Medline].
|
| 31.
|
Suzuki, A.,
M. Iwasaki,
M. Kato, and N. Wagai.
1997.
Sequential operation of ceramide synthesis and ICE cascade in CPT-11-initiated apoptotic death signaling.
Exp. Cell Res.
233:41-47[Medline].
|
| 32.
|
Suzuki, A.,
M. Iwasaki, and N. Wagai.
1997.
Involvement of cytoplasmic serineproteinase and CPP32 subfamily in the molecular machinery of caspase 3 activation during Fas-mediated apoptosis.
Exp. Cell Res.
233:48-55[Medline].
|
| 33.
|
Suzuki, A.,
T. Kawabata, and M. Kato.
1998.
Necessity of interleukin-1 converting enzyme (ICE) cascade in taxotere-initiating death signaling.
Eur. J. Pharmacol.
343:87-92[Medline].
|
| 34.
|
Suzuki, A.,
A. Matsuzawa, and T. Iguchi.
1996.
Downregulation of Bcl-2 is the first step on Fas-mediated apoptosis of male reproductive tracts.
Oncogene
13:31-37[Medline].
|
| 35.
|
Suzuki, A.,
Y. Tsutomi,
K. Akahane,
T. Araki, and M. Miura.
1998.
Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP.
Oncogene
17:931-940[Medline].
|
| 36.
| Suzuki, A., Y. Tsutomi, M. Miura, and K. Akahane.
Caspase 3 inactivation to suppress Fas-mediated apoptosis:
identification of binding domain with p21 and ILP, and inactivation
machinery by p21. Oncogene, in press.
|
| 37.
|
Tewari, M.,
L. T. Quan,
K. O'Rourke,
S. Desnoyers,
Z. Zeng,
D. R. Beidler,
G. G. Poirier,
G. S. Salvesen, and V. M. Dixit.
1995.
Yama/CPP32 , a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase.
Cell
81:801-809[Medline].
|
| 38.
|
Thornbery, N. A.,
T. A. Rano,
E. P. Peterson,
D. M. Rasper,
T. Timkey,
M. Garcia-Calvo,
V. M. Houtzager,
P. A. Nordstorm,
S. Roy,
J. P. Vaillancourt,
K. T. Chapman, and D. W. Nicholson.
1997.
A combinatorial approach defined specificities of members of the caspase family and granzyme B: functional relationships established for key mediators of apoptosis.
J. Biol. Chem.
272:17907-17911[Abstract/Free Full Text].
|
| 39.
|
Wyllie, A. H.,
J. F. R. Kerr, and A. R. Currie.
1980.
Cell death: the significance of apoptosis.
Int. Rev. Cytol.
68:251-306[Medline].
|
| 40.
|
Yang, J.,
X. Liu,
K. Bhalla,
C. N. Kim,
A. M. Ibrado,
J. Cai,
T.-I. Peng,
D. P. Jones, and X. Wang.
1997.
Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked.
Science
275:1129-1132[Abstract/Free Full Text].
|
| 41.
|
Yonehara, S.,
A. Ishii, and M. Yonehara.
1989.
A cell killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor.
J. Exp. Med.
169:1747-1756[Abstract/Free Full Text].
|
| 42.
|
Zou, H.,
W. J. Henzel,
X. Liu,
A. Lutschg, and X. Wang.
1997.
Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3.
Cell
90:405-413[Medline].
|
Molecular and Cellular Biology, May 1999, p. 3842-3847, Vol. 19, No. 5
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Oakley, M. S., McCutchan, T. F., Anantharaman, V., Ward, J. M., Faucette, L., Erexson, C., Mahajan, B., Zheng, H., Majam, V., Aravind, L., Kumar, S.
(2008). Host Biomarkers and Biological Pathways That Are Associated with the Expression of Experimental Cerebral Malaria in Mice. Infect. Immun.
76: 4518-4529
[Abstract]
[Full Text]
-
Crescenzi, E., Palumbo, G., de Boer, J., Brady, H. J.M.
(2008). Ataxia Telangiectasia Mutated and p21CIP1 Modulate Cell Survival of Drug-Induced Senescent Tumor Cells: Implications for Chemotherapy. Clin. Cancer Res.
14: 1877-1887
[Abstract]
[Full Text]
-
Zhan, J., Easton, J. B., Huang, S., Mishra, A., Xiao, L., Lacy, E. R., Kriwacki, R. W., Houghton, P. J.
(2007). Negative Regulation of ASK1 by p21Cip1 Involves a Small Domain That Includes Serine 98 That Is Phosphorylated by ASK1 In Vivo. Mol. Cell. Biol.
27: 3530-3541
[Abstract]
[Full Text]
-
Harms, C., Albrecht, K., Harms, U., Seidel, K., Hauck, L., Baldinger, T., Hubner, D., Kronenberg, G., An, J., Ruscher, K., Meisel, A., Dirnagl, U., von Harsdorf, R., Endres, M., Hortnagl, H.
(2007). Phosphatidylinositol 3-Akt-Kinase-Dependent Phosphorylation of p21Waf1/Cip1 as a Novel Mechanism of Neuroprotection by Glucocorticoids. J. Neurosci.
27: 4562-4571
[Abstract]
[Full Text]
-
Lee, J. Y., Yu, S. J., Park, Y. G., Kim, J., Sohn, J.
(2007). Glycogen Synthase Kinase 3{beta} Phosphorylates p21WAF1/CIP1 for Proteasomal Degradation after UV Irradiation. Mol. Cell. Biol.
27: 3187-3198
[Abstract]
[Full Text]
-
Sohn, D., Essmann, F., Schulze-Osthoff, K., Janicke, R. U.
(2006). p21 Blocks Irradiation-Induced Apoptosis Downstream of Mitochondria by Inhibition of Cyclin-Dependent Kinase-Mediated Caspase-9 Activation. Cancer Res.
66: 11254-11262
[Abstract]
[Full Text]
-
Rodriguez-Vilarrupla, A., Jaumot, M., Abella, N., Canela, N., Brun, S., Diaz, C., Estanyol, J. M., Bachs, O., Agell, N.
(2005). Binding of Calmodulin to the Carboxy-Terminal Region of p21 Induces Nuclear Accumulation via Inhibition of Protein Kinase C-Mediated Phosphorylation of Ser153. Mol. Cell. Biol.
25: 7364-7374
[Abstract]
[Full Text]
-
Kuntzen, C., Sonuc, N., De Toni, E. N., Opelz, C., Mucha, S. R., Gerbes, A. L., Eichhorst, S. T.
(2005). Inhibition of c-Jun-N-terminal-Kinase Sensitizes Tumor Cells to CD95-Induced Apoptosis and Induces G2/M Cell Cycle Arrest. Cancer Res.
65: 6780-6788
[Abstract]
[Full Text]
-
Li, C.-H., Tzeng, S.-L., Cheng, Y.-W., Kang, J.-J.
(2005). Chloramphenicol-induced Mitochondrial Stress Increases p21 Expression and Prevents Cell Apoptosis through a p21-dependent Pathway. J. Biol. Chem.
280: 26193-26199
[Abstract]
[Full Text]
-
Wolfraim, L. A., Walz, T. M., James, Z., Fernandez, T., Letterio, J. J.
(2004). p21Cip1 and p27Kip1 Act in Synergy to Alter the Sensitivity of Naive T Cells to TGF-{beta}-Mediated G1 Arrest through Modulation of IL-2 Responsiveness. J. Immunol.
173: 3093-3102
[Abstract]
[Full Text]
-
Nguyen, D. M., Schrump, W. D., Chen, G. A., Tsai, W., Nguyen, P., Trepel, J. B., Schrump, D. S.
(2004). Abrogation of p21 Expression by Flavopiridol Enhances Depsipeptide-Mediated Apoptosis in Malignant Pleural Mesothelioma Cells. Clin. Cancer Res.
10: 1813-1825
[Abstract]
[Full Text]
-
Lawson, B. R., Baccala, R., Song, J., Croft, M., Kono, D. H., Theofilopoulos, A. N.
(2004). Deficiency of the Cyclin Kinase Inhibitor p21(WAF-1/CIP-1) Promotes Apoptosis of Activated/Memory T Cells and Inhibits Spontaneous Systemic Autoimmunity. JEM
199: 547-557
[Abstract]
[Full Text]
-
Le, N. T.V., Richardson, D. R.
(2003). Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1, but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation. Carcinogenesis
24: 1045-1058
[Abstract]
[Full Text]
-
Gartel, A. L., Tyner, A. L.
(2002). The Role of the Cyclin-dependent Kinase Inhibitor p21 in Apoptosis. Molecular Cancer Therapeutics
1: 639-649
[Abstract]
[Full Text]
-
Burgess, A. J., Pavey, S., Warrener, R., Hunter, L.-J. K., Piva, T. J., Musgrove, E. A., Saunders, N., Parsons, P. G., Gabrielli, B. G.
(2001). Up-Regulation of p21WAF1/CIP1 by Histone Deacetylase Inhibitors Reduces Their Cytotoxicity. Mol. Pharmacol.
60: 828-837
[Abstract]
[Full Text]
-
Ozaki, K., Hanazawa, S.
(2001). Porphyromonas gingivalis Fimbriae Inhibit Caspase-3-Mediated Apoptosis of Monocytic THP-1 Cells under Growth Factor Deprivation via Extracellular Signal-Regulated Kinase-Dependent Expression of p21 Cip/WAF1. Infect. Immun.
69: 4944-4950
[Abstract]
[Full Text]
-
Yang, W., Velcich, A., Mariadason, J., Nicholas, C., Corner, G., Houston, M., Edelmann, W., Kucherlapati, R., Holt, P. R., Augenlicht, L. H.
(2001). p21WAF1/cip1 Is an Important Determinant of Intestinal Cell Response to Sulindac in Vitro and in Vivo. Cancer Res.
61: 6297-6302
[Abstract]
[Full Text]
-
Dai, Y., Yu, C., Singh, V., Tang, L., Wang, Z., McInistry, R., Dent, P., Grant, S.
(2001). Pharmacological Inhibitors of the Mitogen-activated Protein Kinase (MAPK) Kinase/MAPK Cascade Interact Synergistically with UCN-01 to Induce Mitochondrial Dysfunction and Apoptosis in Human Leukemia Cells. Cancer Res.
61: 5106-5115
[Abstract]
[Full Text]
-
Moréno, S. G., Dutrillaux, B., Coffigny, H.
(2001). Status of p53, p21, mdm2, pRb Proteins, and DNA Methylation in Gonocytes of Control and {{gamma}}-Irradiated Rats During Testicular Development. Biol. Reprod.
64: 1422-1431
[Abstract]
[Full Text]
-
Hayashida, M., Kawano, H., Nakano, T., Shiraki, K., Suzuki, A.
(2000). Cell Death Induction by CTL: Perforin/Granzyme B System Dominantly Acts for Cell Death Induction in Human Hepatocellular Carcinoma Cells. Exp. Biol. Med.
225: 143-150
[Abstract]
[Full Text]
-
Schrantz, N., Beney, G. E., Auffredou, M. T., Bourgeade, M. F., Leca, G., Vazquez, A.
(2000). The Expression of p18INK4 and p27kip1 Cyclin-Dependent Kinase Inhibitors Is Regulated Differently During Human B Cell Differentiation. J. Immunol.
165: 4346-4352
[Abstract]
[Full Text]
-
Suzuki, A., Doi, H., Matsuzawa, F., Aikawa, S.-i., Takiguchi, K., Kawano, H., Hayashida, M., Ohno, S.
(2000). Bcl-2 antiapoptotic protein mediates verotoxin II-induced cell death: possible association between Bcl-2 and tissue failure by E. coli O157:H7. Genes Dev.
14: 1734-1740
[Abstract]
[Full Text]